What Is S-Equol? From Soy Daidzein to the Active Metabolite

Part 1 of the Dr. Morgan S-Equol Science Series. This article is an ingredient-science explainer based on published research cited in the Dr. Morgan S-EQUOL PLUS Physician Professional Guide v4. It is for education only and is not medical advice.

The short version

S-equol is not a soy isoflavone. It is what specific gut bacteria make from a soy isoflavone called daidzein — and not everyone has the gut bacteria needed to carry out that conversion. This article explains what S-equol is, where it comes from, and what mechanistic research has — and has not — established.

1. S-equol is not a soy isoflavone

Soy isoflavones are familiar ingredients, but S-equol is not one of them. S-equol is a metabolite produced when specific intestinal bacteria convert daidzein, one of the main soy isoflavones. Think of it this way: the isoflavone is the raw material; S-equol is the finished product — and the manufacturing step happens in your gut, not in a factory.

2. Conversion varies: producers vs. non-producers

Only certain gut bacteria can perform this conversion, and gut microbiota differs from person to person. Published research distinguishes “equol producers” from non-producers, but estimates of their proportions vary by population and study method.

This may explain a familiar puzzle: why soy or soy isoflavones seem to help some people and do nothing for others. The answer may not lie in the soy — it may lie in the gut microbiota.

3. Direct supplementation: bypassing the conversion step

Because conversion capacity varies so widely, the rationale for direct S-equol supplementation is straightforward: instead of relying on each individual’s gut to do the converting, supply the end product of that conversion directly. In the guide’s words, a labelled dose of S-equol supplies S-equol directly rather than requiring the individual to first convert daidzein.

4. ERβ: the most-watched finding in mechanistic research

In mechanistic research, S-equol showed preferential affinity for estrogen receptor beta (ERβ). That finding is a major reason for the scientific interest in this compound.

5. Human pharmacokinetics: what happens after a 10 mg dose

A study in 12 healthy postmenopausal women evaluated single 10 mg and 30 mg doses of S-equol. Direct S-equol was absorbed — and whether or not a woman was an equol producer did not materially change the pharmacokinetic profile. Producers and non-producers absorbed it in essentially the same way.

6. The one-line summary

S-equol is the active substance gut bacteria produce from soy isoflavones — and the ability to make it varies between individuals. Direct supplementation bypasses that conversion gap. Mechanistic research shows preferential ERβ affinity; human pharmacokinetic data show it is absorbed — but mechanism and pharmacokinetics are not efficacy evidence. What does the efficacy evidence actually say? In Part 2, we go through the published human trials one by one.

Coming next — Part 2: The human evidence, trial by trial: Aso 2012, Jenks 2012, Ishiwata 2009, the Daily 2019 systematic review, and the NAMS 2023 position statement.

Selected references for this article

1. Setchell KDR et al. Am J Clin Nutr. 2005;81:1072-1079. PubMed 15883431
2. Setchell KDR et al. J Nutr. 2009;139:2037-2043. PubMed 19776178

The complete reference list for this series appears in Part 4.

Ingredient-science content for education only; not medical advice. S-EQUOL PLUS (NPN 80143622) is a licensed natural health product in Canada; its authorized use is “May reduce severe and frequent menopausal symptoms (such as hot flashes and/or night sweats).” Always read and follow the product label. Licence status can be verified by NPN in Health Canada’s Licensed Natural Health Products Database.